Cytarabine treatment of herpes simplex encephalitis in infants and small children. A report on three cases with a short review of the literature.
Three cytarabine-treated infants and children with herpes simplex encephalitis are presented. The effect of the treatment was excellent in 2 cases. One boy who had a CP syndrome died. It is assumed that the treatment with cytarabine should be started as early as possible with a dosage of 3 mg/kg body weight given intravenously once a day in a single injection for 5 days. No serious side effects have been noted. The advantage of cytarabine over idoxuridine, especially when treating small children and herpetic infections in the central nervous system, are emphasized.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001921:Brain / Q000382:microbiology; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D004671:Encephalitis, Arbovirus / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D018139:Simplexvirus / Q000302:isolation & purification
D003561:Cytarabine